{"id":4271,"date":"2001-04-17T20:47:08","date_gmt":"2001-04-17T19:47:08","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=4271"},"modified":"2014-06-12T14:07:14","modified_gmt":"2014-06-12T14:07:14","slug":"topical-docosanol-may-be-beneficial-in-treating-hiv-related-kaposis-sarcoma","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/4271","title":{"rendered":"Topical docosanol may be beneficial in treating HIV-related Kaposi&#8217;s sarcoma"},"content":{"rendered":"<p><strong>The antiviral agent docosanol appears safe and may be effective as a topical treatment for Kaposi&#8217;s sarcoma (KS) lesions in HIV-positive\u00a0patients, according to the results of a pilot study published in the January 1st issue of AIDS Research and Human Retroviruses.<\/strong><\/p>\n<p>Docosanol has shown activity against a broad spectrum of lipid-enveloped viruses in vitro, is currently approved by the US Food and Drug Administration for the topical treatment of recurrent oral-facial herpes simplex infections.<\/p>\n<p>Dr. Michael J. Scolaro, from the Scolaro Medical Coalition, in Beverly Hills, California, and colleagues assessed the safety and efficacy of topical docosanol 10% cream in 10 HIV-1-positive\u00a0KS patients treated with the medication five times daily for 4 weeks. At the end of the 4-week period, all patients elected to have their treatment extended for up to 35 weeks.<\/p>\n<p>The researchers point out that the current study&#8217;s ability to determine efficacy is limited because it was an open-label study without a placebo group and because patients did not discontinue their established antiviral regimens. In addition, ACTG response criteria were not employed.<\/p>\n<p>&#8220;The study has nevertheless shown that docosanol can be used safely in immunocompromised individuals and that it may exert clinical benefits on cutaneous KS lesions in HIV-positive\u00a0patients, indicating that docosanol 10% cream merits further investigation as a topical therapy for the treatment of cutaneous KS disease,&#8221; Dr. Scolaro&#8217;s team concludes.<\/p>\n<p>Reference:<\/p>\n<p>AIDS Res Hum Retroviruses 2001;17:35-43.<\/p>\n<p>Source: Reuters Health<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The antiviral agent docosanol appears safe and may be effective as a topical treatment for Kaposi&#8217;s sarcoma (KS) lesions in HIV-positive\u00a0patients, according to the results of a pilot study published in the January 1st issue of AIDS Research and Human &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[31],"tags":[],"class_list":["post-4271","post","type-post","status-publish","format-standard","hentry","category-opportunistic-infections-coinfections-and-complications"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/4271","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=4271"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/4271\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=4271"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=4271"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=4271"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}